

Extraordinary Meeting of Q-Med AB (publ)

The Board of Directors of Q-Med AB (publ) has published a notice to attend the Extraordinary General Meeting, which will be held on Wednesday February 4, 2009 at 3 p.m. on Q-Med's premises. Entrance from Fyrisvallsgatan 5, Uppsala, Sweden. A notice has been published in Upsala Nya Tidning, Svenska Dagbladet and in Post- och Inrikes Tidningar (Swedish Official Gazette). The complete notice of the Extraordinary General Meeting in English can be found on the corporate web site www.q-med.com and is also attached.

Q-Med AB (publ)

The Board

Queries should be addressed to:

Kristin Ermanbriks, Manager Corporate Administration
Tel: +46 (0) 70 974 9071

*Q-Med AB is a rapidly growing and profitable biotechnology/medical device company. The company develops, manufactures, markets, and sells primarily medical implants. The majority of the products are based on the company's patented technology, **NASHA**[™], for the production of stabilized non-animal hyaluronic acid. The product portfolio today contains: **Restylane**[®] for filling lines and folds, contouring and creating volume in the face, **Macrolane**[™] for body contouring, **Durolane**[™] for the treatment of osteoarthritis of the hip and knee joints, **Deflux**[®] for the treatment of vesicoureteral reflux, VUR, (a malformation of the urinary bladder) in children, and **Solesta**[™] for the treatment of fecal incontinence. Sales are made through the company's own subsidiaries or distributors in over 70 countries. Q-Med today has just over 700 coworkers, with close to 500 at the company's head office and production facility in Uppsala, Sweden. Q-Med AB is listed in the Mid Cap segment of the OMX Nordic Exchange in Stockholm.*
